Skip to main content
Figure 1 | Kinetoplastid Biology and Disease

Figure 1

From: Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13–15 June, 2006

Figure 1

Schematic representation of decision matrix for short-term objectives (3 years). ctivities related to trials of selected combination of anti-parasitic drugs will proceed in parallel with development of immuno-chemotherapy approach using available drugs, immun-modulators, with or without leishmanial antigens. Efforts will be focused on enhancing the quality of clinical trials through development of standard protocols and ICH-GCP training.

Back to article page

Kinetoplastid Biology and Disease

ISSN: 1475-9292